CBD Reduced Seizures and Extended Survival in a Mouse Model of Rare Childhood Epilepsy | Research

The takeaway

In mice modeling developmental and epileptic encephalopathy type 1 (DEE1), daily CBD treatment reduced seizure severity and frequency while significantly extending lifespan, working through anti-inflammatory and ion channel mechanisms.

Pediatric neurologists, epilepsy researchers, and families affected by rare developmental epilepsy syndromes.

What the researchers found

Daily CBD (100 mg/kg) for 7 days reduced the severity and frequency of spontaneous recurrent seizures and significantly extended lifespan in Arx(GCG)7/Y mice. CBD activated PPARγ expression, desensitized TRPV1 channels, counteracted proinflammatory gene expression, and restored normal microglial morphology.

Why it matters

DEE1 is a devastating drug-resistant childhood epilepsy with high mortality. CBD is already FDA-approved for some childhood epilepsies (Epidiolex), and this study provides mechanistic evidence supporting its potential effectiveness in DEE1 specifically.

The numbers in context

CBD dose: 100 mg/kg/day intraperitoneally for 7 days. CBD reduced severity and frequency of spontaneous seizures. Significantly extended survival. Reduced expression of proinflammatory genes Ptgs2, Mmp9, Il12, Cd68, Ccl2, and Irf3.

How the study worked

Arx(GCG)7/Y mice (genetic DEE1 model) received daily intraperitoneal CBD (100 mg/kg) for 7 days. Epileptic phenotype was evaluated via video monitoring and scoring matrix. Molecular effects assessed by RT-PCR, Western blotting, Iba1 immunostaining, Sholl analysis, and patch-clamp electrophysiology.

What this study cannot tell us

Mouse model with high-dose intraperitoneal CBD, which may not reflect human oral dosing. Short 7-day treatment. DEE1 is extremely rare, limiting direct clinical applicability. Single dose level tested.

How to read the evidence

Well-designed preclinical study with multiple mechanistic endpoints, but high-dose intraperitoneal administration and short duration limit clinical translation.

When this study was published

Published 2025.

The bigger picture

CBD's success in rare epilepsy models continues to expand the potential indications for cannabinoid-based epilepsy treatments. The detailed mechanistic findings — PPARγ activation, TRPV1 desensitization, and anti-inflammatory effects — help explain how CBD works beyond simple seizure suppression.

Questions still open

Would oral CBD at achievable human doses produce similar effects in DEE1 patients? Could CBD be combined with existing anti-epileptic drugs for DEE1? Which of CBD's multiple mechanisms is most important for the anti-seizure effect?

Common questions

Is CBD already approved for childhood epilepsy?

Yes — Epidiolex (purified CBD) is FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. This study suggests CBD may also benefit DEE1, which is currently drug-resistant, but human trials would be needed.

How does CBD stop seizures?

This study found CBD works through multiple mechanisms: activating anti-inflammatory PPARγ pathways, desensitizing TRPV1 ion channels, reducing proinflammatory gene expression, and restoring normal microglial (immune cell) function in the brain.

Read the original research

Cannabidiol attenuates epileptic phenotype and increases survival in a mouse model of developmental and epileptic encephalopathy type 1.

Epilepsia, 66(10), 4035-4052

View on PubMed ↗Publisher’s paper ↗

Citation

Verrillo, Lucia; Iannotti, Fabio Arturo; Drongitis, Denise; Martinello, Katiuscia; Poeta, Loredana; Barra, Adriano; Terrone, Gaetano; Fucile, Sergio; Di Marzo, Vincenzo; Miano, Maria Giuseppina. (2025). Cannabidiol attenuates epileptic phenotype and increases survival in a mouse model of developmental and epileptic encephalopathy type 1.. Epilepsia, 66(10), 4035-4052. https://doi.org/10.1111/epi.18522